WINTON GROUP Ltd Buys Shares of 20,536 LivaNova PLC (NASDAQ:LIVN)

WINTON GROUP Ltd purchased a new stake in LivaNova PLC (NASDAQ:LIVN) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 20,536 shares of the company’s stock, valued at approximately $951,000.

Several other large investors have also modified their holdings of LIVN. Vanguard Group Inc. increased its position in LivaNova by 12.7% during the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company’s stock worth $108,823,000 after purchasing an additional 265,291 shares in the last quarter. Point72 Asset Management L.P. raised its position in shares of LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after buying an additional 806,374 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of LivaNova by 0.6% during the third quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock valued at $70,676,000 after buying an additional 8,331 shares during the period. Emerald Advisers LLC boosted its position in LivaNova by 8.2% during the fourth quarter. Emerald Advisers LLC now owns 752,540 shares of the company’s stock worth $34,850,000 after acquiring an additional 57,035 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in LivaNova by 17.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock worth $32,678,000 after acquiring an additional 93,311 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Stock Down 1.2 %

LIVN opened at $39.13 on Friday. The company has a market cap of $2.13 billion, a PE ratio of 93.17 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a 1 year low of $36.85 and a 1 year high of $64.48. The firm has a 50 day moving average price of $44.51 and a 200 day moving average price of $48.48.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on LIVN shares. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 25th. Mizuho lowered their price target on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research note on Monday, March 17th. Stifel Nicolaus decreased their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Finally, Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, LivaNova has a consensus rating of “Buy” and a consensus price target of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.